Lumida
/LUNG
⌘K
Pulmonx Corp

Pulmonx Corp

LUNG
$1.85USD↑+0.00%+0.00 today

MARKET CAP

79.5M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$2 – $2

52W RANGE

$1
$3

AI Summary

Stalk
TrimMedium

In a Stage 4 decline featuring persistent lower highs and lower lows, the medium-term bias remains bearish under declining EMAs and distribution volume. Short-term timing is neutral as price tightly tracks flat EMAs and is oversold, suggesting risk of a bounce. Therefore, execution is deferred with a Trim approach, awaiting stalled rallies into structural resistance.

  • ↑FY26 revenue guided at $90–92 M supports growth outlook
  • ↑Q2 adjusted EBITDA loss fell to $5.1 M from $8.4 M YoY
  • ↓Q2 revenue declined to $22.8 M due to China distributor gap
Full analysis →

Buying

5

institutions

Selling

2

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

SELL882.49 K1.15 M+-1.78 M-66.6%0.00%
AC

Aqr Capital Management LLC

Q2 2026

BUY744.96 K968.45 K+387.38 K+110.0%0.00%
RT

Renaissance Technologies LLC

Q2 2026

BUY425.11 K552.64 K+104.81 K+33.8%0.00%
AC

Adar1 Capital Management, LLC

Q2 2026

BUY404.50 K525.85 K+30.00 K+8.8%0.02%
CA

Citadel Advisors LLC

Q2 2026

BUY402.10 K522.74 K+335.00 K+503.8%0.00%
MM

Millennium Management LLC

Q2 2026

BUYNEW209.56 K272.42 K+209.56 K+0.0%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

SELL2.25 K2.99 K+-385.85 K-99.3%0.00%